Revvity, Inc. 2026 2. Çeyrek Kazanç Çağrı Özeti

Revvity, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Wed, August 5, 2026 at 4:33 AM GMT+3 3 min read

Revvity, Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Performance Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management attributes the Q2 performance beat to a constructive spending environment in pharma and biotech, marking the third consecutive quarter of improving end-market conditions.
A definitive increase in orders is being driven by both traditional and non-traditional customers building AI-driven drug discovery platforms, which require physical validation through biological data generation.
The 'Lab-in-the-Loop' workflow is emerging as a critical strategic framework where AI models suggest experiments that generate proprietary data, which is then fed back into the models to compress discovery timelines.
High-content screening demand for the new Opera Phenix OptIQ instrument remains robust, with order velocity currently outpacing near-term production capacity despite additional resource allocation.
The Diagnostics franchise continues to serve as a foundational strength, with broad-based growth in newborn screening and immunodiagnostics outside of China offsetting macro birth rate pressures.
Strategic divestiture of the China immunodiagnostics business is progressing with a definitive agreement signed, allowing the company to exit a structurally challenging environment and focus on higher-margin differentiated capabilities.

Outlook and Strategic Assumptions

Full-year organic growth guidance was raised to 4% to 5%, reflecting increased optimism regarding the sustainability of the pharma and biotech recovery observed in the first half.
Management expects a return to strong double-digit growth in the Signals software business in the second half of the year, driven by a heavy schedule of contract renewals and new product launches like LabGistics.
The company plans to reinvest approximately half of the $16 million tariff refund benefit into strategic initiatives, supply chain capacity, and personnel to capitalize on emerging AI infrastructure demand.
Guidance assumes reproductive health growth will moderate to low-to-mid single digits in the second half as the company laps difficult comparisons from the Genomics England contract.
Gross leverage is targeted to fall below 3x by year-end following the retirement of a EUR 500 million note, providing increased balance sheet flexibility for future capital allocation.

Operational and Risk Factors

A $16 million one-time benefit from tariff-related refunds significantly impacted Q2 margins and EPS, though management noted underlying operating performance was also ahead of expectations.
The divestiture of the China immunodiagnostics business is expected to close by the end of 2027, with pro forma reporting already excluding this segment to provide a clearer view of core operations.
Instrument backlog has reached its strongest position in 3 to 4 years, partly due to the complexity of manufacturing high-end systems like the OptIQ, which creates a timing-related revenue shift into the second half.
Latent TB pressures continue to act as a headwind in the Americas, though this is being mitigated by strength in other diagnostic categories.

Q&A Insights

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Composition and sustainability of the Life Sciences instrument backlog

Management confirmed the backlog is primarily composed of non-commoditized, high-value instruments like the Opera Phenix OptIQ, which are essential for AI data generation.
The backlog build is viewed as a positive indicator of a multi-year AI infrastructure cycle rather than a temporary supply chain bottleneck.

Reagent growth trajectory within Life Sciences Solutions

Reagents grew in the low single digits in the first half, but management expects a step-up to mid-single-digit growth by the fourth quarter.
The increase in instrument placements is expected to drive future reagent pull-through as customers transition from infrastructure setup to active screening and validation.

Impact of AI on customer base and market expansion

Revvity is seeing demand from 'non-traditional' customers, including non-profits and tech-centric firms building massive biological data sets for AI training.
Management believes they are in the 'very early innings' of this transformation, making it difficult to fully quantify the long-term magnitude of the AI-related opportunity.